Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGD4C-p21Ras-scFv
- Development stage
- Preclinical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RGD4C-p21Ras-scFv is a recombinant fusion protein designed to target the intracellular p21Ras protein in ras-driven cancers. It consists of a single-chain variable fragment (scFv) antibody that binds to both mutant and wild-type p21Ras, linked to an RGD4C membrane-penetrating peptide. While traditional scFv antibodies are typically unable to cross the cell membrane, the RGD4C peptide facilitates the internalization of the scFv into the cytoplasm of tumor cells. Once inside, the agent binds to p21Ras, inhibiting its signaling activity, which leads to the suppression of tumor cell migration and proliferation, and the induction of apoptosis. Research has specifically highlighted its efficacy against the human colorectal cancer cell line SW480, and pilot-scale production processes have been established to support further development.
- Other names
- RGD4C-anti-p21Ras scFvRGD-4C-anti-p21Ras scFvRGD 4C-anti-p21Ras scFvRGD4C-p21Ras-scFv conjugateRGD-4C-p21Ras-scFv conjugateRGD 4C-p21Ras-scFv conjugate
02
Targets
HRAS (H-Ras protein)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on RGD4C-p21Ras-scFv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGD4C-p21Ras-scFv.